|
The purpose of detection of acute leukemia (AL) content of different types and subtypes, and at different stages of the same leukemia serum interleukin -12 (IL-12), gamma-interferon (IFN-γ) and lactate dehydrogenase (LDH) change, to explore the significance of the three in the AL diagnosis, condition monitoring, efficacy observed and prognosis. Methods 79 cases of newly diagnosed patients; complete remission (CR) patients with 58 cases, including 46 cases of newly diagnosed cases of remission after chemotherapy, 12 were new cases; recurrence in 42 patients, including 12 cases of our research diagnosis group by recurrence in remission after chemotherapy, and another 30 cases of new cases; 20 healthy persons as normal controls, respectively, by enzyme-linked immunoassay (ELISA) method for the determination of serum IL-12 and IFN-γ measured serum LDH rate method content. Results the ① AL newly diagnosed patients with serum IL-12, IFN-γ content was significantly reduced and serum LDH was significantly increased, compared with the normal control group showed a significant difference (t '= 3.58 to 8.47; P <0.01). Serum IL-12 and IFN-γ levels showed a significant positive correlation (r = 0.498, P <0.01), both with serum LDH levels showed a significant negative correlation (r = 0.634,0.510; P <0.01). Acute myeloid leukemia (AML) patients were significantly lower than in serum IL-12 with acute lymphoblastic leukemia (ALL) patients (t = 2.78, P <0.01), serum IFN-γ and LDH were no significant differences between the two (t = 2.03,2.03, P> 0.05). Different gender between serum IL-12, IFN-γ and LDH levels without significant difference; ② CR patient serum IL-12, IFN-γ were significantly elevated LDH levels significantly lower compared with the newly diagnosed group were significantly difference (t, t '= 2.86 ~~ 7.38, P <0.05). Relapsed patients serum IL-12, IFN-γ levels are significantly lower, and LDH levels increased again, with the CR group, there were significant differences (t, t '= 4.03 to 17.47, P <0.05), with newly diagnosed group The three had no significant difference; ③ The AL FAB subtypes, each subtype between IL-12, IFN-γ, LDH content had no significant difference (F = 0.114 to 0.530, P> 0.05). According to the type of immune credits, B-ALL serum IL-12 content was significantly higher than in patients with T-ALL, the difference was significant (t = 2.31, P <0.05), and IFN-γ, LDH content in T-ALL and B- ALL no significant difference (t = 0.27,0.099; P> 0.05); ④ need multiple treatments to alleviate or still does not alleviate the patients whose serum IL-12, IFN-γ decrease significantly higher than sensitive to chemotherapy patients, there are significant differences in serum LDH increased range. The Conclusion ① AL newly diagnosed serum IL-12, IFN-γ significantly reduced, LDH level significantly higher IL-12 and IFN-γ was significantly positively correlated, suggesting that IL-12, IFN-γ, LDH and AL occurrence related. ② AL patients after CR serum IL-12, IFN-γ content was significantly increased LDH levels to reduce the recurrence of IL-12, IFN-γ content again reduce, LDH along with it. Suggest that serum IL-12, IFN-γ and LDH and AL progression of the disease related. ③ need multiple treatments to alleviate or sustained can not be relieved, serum IL-12, IFN-γ and LDH lowers and raises the amplitude is significantly higher than in patients sensitive to chemotherapy drugs, sustained reductions and increased poor prognosis, indicating IL-12, IFN-γ and LDH AL treatment can be used as an important indicator of the AL prognosis. The ④ serum IL-12, IFN-γ and LDH and AL FAB classification independent B-ALL patients with serum IL-12 were significantly higher than T-ALL patients, suggesting that IL-12 with ALL immunophenotyping related. ⑤ by clinical follow-up found that, once part of the CR patients IL-12, IFN-γ and LDH serological changes, patients often relapse within a short period, suggesting that serum IL-12, IFN-γ and LDH monitoring conducive to relapse of leukemia forecast, also can guide clinical treatment.
|